Renal Cell Carcinoma (RCC) has historically been considered a radioresistant cancer, and radiotherapy was usually delivered with a palliative goal. Stereotactic ablative radiotherapy (SABR) allows the delivery of high doses on small treatment volumes in a safe and effective way, thus opening the doors to new applicationsof radiotherapy both in the treatment of the primary and oligometastasic disease. Aim of the current review is to explore the state of art of SABR in the therapeutic approach to RCC.
Stereotactic ablative radiation therapy in renal cell carcinoma : from oligometastatic to localized disease / F. Alongi, S. Arcangeli, L. Triggiani, R. Mazzola, M. Buglione di Monale e Bastia, S. Fersino, A. Baiguini, B.A. Jereczek-Fossa, S.M. Magrini. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 117:(2017), pp. 48-56. [10.1016/j.critrevonc.2017.07.004]
Stereotactic ablative radiation therapy in renal cell carcinoma : from oligometastatic to localized disease
B.A. Jereczek-Fossa;
2017
Abstract
Renal Cell Carcinoma (RCC) has historically been considered a radioresistant cancer, and radiotherapy was usually delivered with a palliative goal. Stereotactic ablative radiotherapy (SABR) allows the delivery of high doses on small treatment volumes in a safe and effective way, thus opening the doors to new applicationsof radiotherapy both in the treatment of the primary and oligometastasic disease. Aim of the current review is to explore the state of art of SABR in the therapeutic approach to RCC.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
